Literature DB >> 24132104

Tyrosine kinase gene rearrangements in epithelial malignancies.

Alice T Shaw1, Peggy P Hsu, Mark M Awad, Jeffrey A Engelman.   

Abstract

Chromosomal rearrangements that lead to oncogenic kinase activation are observed in many epithelial cancers. These cancers express activated fusion kinases that drive the initiation and progression of malignancy, and often have a considerable response to small-molecule kinase inhibitors, which validates these fusion kinases as 'druggable' targets. In this Review, we examine the aetiologic, pathogenic and clinical features that are associated with cancers harbouring oncogenic fusion kinases, including anaplastic lymphoma kinase (ALK), ROS1 and RET. We discuss the clinical outcomes with targeted therapies and explore strategies to discover additional kinases that are activated by chromosomal rearrangements in solid tumours.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24132104      PMCID： PMC3902129          DOI： 10.1038/nrc3612

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  159 in total

1.  Thyroid cancer after Chernobyl.

Authors:  V S Kazakov; E P Demidchik; L N Astakhova
Journal:  Nature       Date:  1992-09-03       Impact factor: 49.962

2.  Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A.

Authors:  I Bongarzone; N Monzini; M G Borrello; C Carcano; G Ferraresi; E Arighi; P Mondellini; G Della Porta; M A Pierotti
Journal:  Mol Cell Biol       Date:  1993-01       Impact factor: 4.272

3.  PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas.

Authors:  M Grieco; M Santoro; M T Berlingieri; R M Melillo; R Donghi; I Bongarzone; M A Pierotti; G Della Porta; A Fusco; G Vecchio
Journal:  Cell       Date:  1990-02-23       Impact factor: 41.582

4.  Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident.

Authors:  T Ito; T Seyama; K S Iwamoto; T Mizuno; N D Tronko; I V Komissarenko; E D Cherstovoy; Y Satow; N Takeichi; K Dohi
Journal:  Lancet       Date:  1994-07-23       Impact factor: 79.321

5.  Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.

Authors:  I Bongarzone; M G Butti; S Coronelli; M G Borrello; M Santoro; P Mondellini; S Pilotti; A Fusco; G Della Porta; M A Pierotti
Journal:  Cancer Res       Date:  1994-06-01       Impact factor: 12.701

6.  A sequence analysis of the genomic regions involved in the rearrangements between TPM3 and NTRK1 genes producing TRK oncogenes in papillary thyroid carcinomas.

Authors:  M G Butti; I Bongarzone; G Ferraresi; P Mondellini; M G Borrello; M A Pierotti
Journal:  Genomics       Date:  1995-07-01       Impact factor: 5.736

7.  TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas.

Authors:  A Greco; M A Pierotti; I Bongarzone; S Pagliardini; C Lanzi; G Della Porta
Journal:  Oncogene       Date:  1992-02       Impact factor: 9.867

8.  In vitro irradiation is able to cause RET oncogene rearrangement.

Authors:  T Ito; T Seyama; K S Iwamoto; T Hayashi; T Mizuno; N Tsuyama; K Dohi; N Nakamura; M Akiyama
Journal:  Cancer Res       Date:  1993-07-01       Impact factor: 12.701

9.  Oncogenic rearrangements of the RET proto-oncogene in papillary thyroid carcinomas from children exposed to the Chernobyl nuclear accident.

Authors:  L Fugazzola; S Pilotti; A Pinchera; T V Vorontsova; P Mondellini; I Bongarzone; A Greco; L Astakhova; M G Butti; E P Demidchik
Journal:  Cancer Res       Date:  1995-12-01       Impact factor: 12.701

10.  The DNA rearrangement that generates the TRK-T3 oncogene involves a novel gene on chromosome 3 whose product has a potential coiled-coil domain.

Authors:  A Greco; C Mariani; C Miranda; A Lupas; S Pagliardini; M Pomati; M A Pierotti
Journal:  Mol Cell Biol       Date:  1995-11       Impact factor: 4.272
View more
  126 in total

1.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

Review 2.  TRK Inhibitors in Non-Small Cell Lung Cancer.

Authors:  Guilherme Harada; Aline Bobato Lara Gongora; Cesar Martins da Costa; Fernando Costa Santini
Journal:  Curr Treat Options Oncol       Date:  2020-04-23

Review 3.  Emerging Gene Fusion Drivers in Primary and Metastatic Central Nervous System Malignancies: A Review of Available Evidence for Systemic Targeted Therapies.

Authors:  Priscilla K Brastianos; Franziska Maria Ippen; Umbreen Hafeez; Hui K Gan
Journal:  Oncologist       Date:  2018-04-27

4.  EGFR Fusions as Novel Therapeutic Targets in Lung Cancer.

Authors:  Kartik Konduri; Jean-Nicolas Gallant; Young Kwang Chae; Francis J Giles; Barbara J Gitlitz; Kyle Gowen; Eiki Ichihara; Taofeek K Owonikoko; Vijay Peddareddigari; Suresh S Ramalingam; Satyanarayan K Reddy; Beth Eaby-Sandy; Tiziana Vavalà; Andrew Whiteley; Heidi Chen; Yingjun Yan; Jonathan H Sheehan; Jens Meiler; Deborah Morosini; Jeffrey S Ross; Philip J Stephens; Vincent A Miller; Siraj M Ali; Christine M Lovly
Journal:  Cancer Discov       Date:  2016-04-21       Impact factor: 39.397

Review 5.  Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Authors:  Justin M Drake; John K Lee; Owen N Witte
Journal:  Mol Cell Biol       Date:  2014-02-24       Impact factor: 4.272

6.  RET fusion as a novel driver of medullary thyroid carcinoma.

Authors:  Elizabeth G Grubbs; Patrick Kwok-Shing Ng; Jacquelin Bui; Naifa L Busaidy; Ken Chen; Jeffrey E Lee; Xinyan Lu; Hengyu Lu; Funda Meric-Bernstam; Gordon B Mills; Gary Palmer; Nancy D Perrier; Kenneth L Scott; Kenna R Shaw; Steven G Waguespack; Michelle D Williams; Roman Yelensky; Gilbert J Cote
Journal:  J Clin Endocrinol Metab       Date:  2014-12-29       Impact factor: 5.958

7.  Clinical development and approval of second generation ALK inhibitors for ALK rearranged lung cancer.

Authors:  Daniel B Costa
Journal:  Transl Lung Cancer Res       Date:  2014-12

8.  Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer.

Authors:  Lian-Xiang Luo; Ying Li; Yu-Zhen Niu; Yu-Wei Wang; Qian-Qian Wang; Xing-Xing Fan; Jia-Hui Xu; Liang Liu; Elaine Lai-Han Leung; Xiao-Jun Yao
Journal:  Medchemcomm       Date:  2017-08-25       Impact factor: 3.597

9.  Efficacy and Tolerability of Pyrazolo[1,5-a]pyrimidine RET Kinase Inhibitors for the Treatment of Lung Adenocarcinoma.

Authors:  Casey J N Mathison; Donatella Chianelli; Paul V Rucker; John Nelson; Jason Roland; Zhihong Huang; Yang Yang; Jiqing Jiang; Yun Feng Xie; Robert Epple; Badry Bursulaya; Christian Lee; Mu-Yun Gao; Jennifer Shaffer; Sergio Briones; Yelena Sarkisova; Anna Galkin; Lintong Li; Nanxin Li; Chun Li; Su Hua; Shailaja Kasibhatla; Jacqueline Kinyamu-Akunda; Rie Kikkawa; Valentina Molteni; John E Tellew
Journal:  ACS Med Chem Lett       Date:  2020-02-12       Impact factor: 4.345

10.  Novel identification of STAT1 as a crucial mediator of ETV6-NTRK3-induced tumorigenesis.

Authors:  Jinah Park; Junil Kim; Bora Park; Kyung-Min Yang; Eun Jin Sun; Cristina E Tognon; Poul H Sorensen; Seong-Jin Kim
Journal:  Oncogene       Date:  2018-02-02       Impact factor: 9.867
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.